Influenza

The drug reduces the time to improvement of flu symptoms in patients having at least 1 high-risk factor.

Authors say comparing mortality rates between the 2 conditions is a threat to public health.

Despite proven benefits, there is still a need for more intensive or targeted patient motivational strategies.

Flu burden for children can be reduced by improving adherence to a two-dose series of flu vaccinations.

Providers should consider flu in their diagnoses of patients who present at the hospital with less recognized manifestations.

Benefits from HD-IIV might be greater for protection against influenza B/Yamagata and influenza A(H3N2) than for influenza A(H1N1) pdm09.

Though weekly activity has slowed, experts insist the national activity remains high overall.

The FDA has approved a quadrivalent formula of the adjuvanted seasonal influenza vaccine from Seqiris.

Younger patients display increased susceptibility to H1N1 relative to H3N2, according to study findings.

In the midst of another busy flu season, officials stress the importance of vaccinating older at-risk persons.

Although much attention is on coronavirus, patients might need to be more concerned with the flu.

The newest virus scare has killed one-tenth as many patients as influenza this season, yet public concern fixates on the smaller issue.

Seqirus announced approval of influenza A monovalent vaccine, adjuvanted (Audenz™) for protection against influenza A in a release on Monday morning.

New weekly report data shows the count of jurisdictions with high influenza-like illness activity has risen again.

New data for the 2019-2020 season shows the virus is at a high activity, but disease severity is moderate.

Though vaccination rates are decreasing in children and adolescents overall, it is not due to consideration of previous season's successes or failures.

The new vaccine is expected to be available for the 2020-2021 influenza season.

Fewer than 2% of all patients hospitalized with pneumonia in 2014 received the vaccination.

Xofluza is currently being evaluated in a phase 3 development program for the reduced transmission of flu from an infected person to healthy people.

The CDC Influenza Division medical director reported new findings at IDWeek showing older patients with influenza subtype A were more likely to be hospitalized.

New findings presented at IDWeek show vaccinated children have inconsistent protection from the A(H3N2) flu subtype.

How a community-based assessment can show physicians the ways in which the flu spreads.

The CDC Influenza Division medical officer discusses findings from their pediatric assessment at IDWeek.

A pair of phase 3 trials show the single-dose oral drug could have expanded benefits for influenza, just months before an sNDA ruling.

Early research found that e-cigarette use affects the immune system response to the flu virus and the effects are different for female and male users.